| pubmed-article:11173925 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11173925 | lifeskim:mentions | umls-concept:C0034721 | lld:lifeskim |
| pubmed-article:11173925 | lifeskim:mentions | umls-concept:C0034693 | lld:lifeskim |
| pubmed-article:11173925 | lifeskim:mentions | umls-concept:C0026336 | lld:lifeskim |
| pubmed-article:11173925 | lifeskim:mentions | umls-concept:C0022614 | lld:lifeskim |
| pubmed-article:11173925 | lifeskim:mentions | umls-concept:C0079883 | lld:lifeskim |
| pubmed-article:11173925 | lifeskim:mentions | umls-concept:C0443306 | lld:lifeskim |
| pubmed-article:11173925 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:11173925 | lifeskim:mentions | umls-concept:C0596988 | lld:lifeskim |
| pubmed-article:11173925 | lifeskim:mentions | umls-concept:C0243076 | lld:lifeskim |
| pubmed-article:11173925 | lifeskim:mentions | umls-concept:C0813872 | lld:lifeskim |
| pubmed-article:11173925 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:11173925 | pubmed:dateCreated | 2001-2-22 | lld:pubmed |
| pubmed-article:11173925 | pubmed:abstractText | The neuroprotective effects of the NMDA antagonists MK-801 and ketamine were analyzed in a mutant strain of Han-Wistar rats which develop neurodegeneration in the hippocampus and cerebellum. Previous experiments have shown that the progressive neuronal degeneration observed in this mutant may be the result of a dysfunctional glutamatergic system. For MK-801 studies, mutants were injected in a chronic paradigm with (+)MK-801 or its weaker acting isomer (-)MK-801 at a dose of 1 mg/kg. Ketamine studies consisted of both acute (50 mg/kg once) and chronic (10 mg/kg multiple times) injection paradigms. MK-801-treated mutants exhibited longer life spans (8-23%) compared to saline-injected mutants. Ketamine-injected mutants in both paradigms also lived slightly longer (6-9%) than the saline mutants. Motor skill deterioration was monitored in an open-field test, and after 50 days of age the MK-801 and ketamine mutants displayed over 20% greater motor skill activity than the saline mutants. In the cerebellum, mutants treated with ketamine and both forms of MK-801 had 10-20% more Purkinje cells surviving at 55 days than the saline mutants. Further, the density of CA3c pyramidal hippocampal neurons in ketamine and MK-801-treated mutants as compared to saline mutants appeared to be greater upon qualitative analysis. This study shows that these mutants derive some protective effects from the NMDA antagonists MK-801 and ketamine, confirming glutamate-induced excitotoxicity as a possible cause of neuronal degeneration in this mutant strain of rat. | lld:pubmed |
| pubmed-article:11173925 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11173925 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11173925 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11173925 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11173925 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11173925 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11173925 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11173925 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11173925 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11173925 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11173925 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11173925 | pubmed:issn | 0378-5866 | lld:pubmed |
| pubmed-article:11173925 | pubmed:author | pubmed-author:KhannaAA | lld:pubmed |
| pubmed-article:11173925 | pubmed:author | pubmed-author:CohenR WRW | lld:pubmed |
| pubmed-article:11173925 | pubmed:author | pubmed-author:CromwellH CHC | lld:pubmed |
| pubmed-article:11173925 | pubmed:author | pubmed-author:BrunsonK LKL | lld:pubmed |
| pubmed-article:11173925 | pubmed:copyrightInfo | Copyright 2001 S. Karger AG, Basel | lld:pubmed |
| pubmed-article:11173925 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11173925 | pubmed:volume | 23 | lld:pubmed |
| pubmed-article:11173925 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11173925 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11173925 | pubmed:pagination | 31-40 | lld:pubmed |
| pubmed-article:11173925 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:11173925 | pubmed:meshHeading | pubmed-meshheading:11173925... | lld:pubmed |
| pubmed-article:11173925 | pubmed:meshHeading | pubmed-meshheading:11173925... | lld:pubmed |
| pubmed-article:11173925 | pubmed:meshHeading | pubmed-meshheading:11173925... | lld:pubmed |
| pubmed-article:11173925 | pubmed:meshHeading | pubmed-meshheading:11173925... | lld:pubmed |
| pubmed-article:11173925 | pubmed:meshHeading | pubmed-meshheading:11173925... | lld:pubmed |
| pubmed-article:11173925 | pubmed:meshHeading | pubmed-meshheading:11173925... | lld:pubmed |
| pubmed-article:11173925 | pubmed:meshHeading | pubmed-meshheading:11173925... | lld:pubmed |
| pubmed-article:11173925 | pubmed:meshHeading | pubmed-meshheading:11173925... | lld:pubmed |
| pubmed-article:11173925 | pubmed:meshHeading | pubmed-meshheading:11173925... | lld:pubmed |
| pubmed-article:11173925 | pubmed:meshHeading | pubmed-meshheading:11173925... | lld:pubmed |
| pubmed-article:11173925 | pubmed:meshHeading | pubmed-meshheading:11173925... | lld:pubmed |
| pubmed-article:11173925 | pubmed:meshHeading | pubmed-meshheading:11173925... | lld:pubmed |
| pubmed-article:11173925 | pubmed:meshHeading | pubmed-meshheading:11173925... | lld:pubmed |
| pubmed-article:11173925 | pubmed:meshHeading | pubmed-meshheading:11173925... | lld:pubmed |
| pubmed-article:11173925 | pubmed:meshHeading | pubmed-meshheading:11173925... | lld:pubmed |
| pubmed-article:11173925 | pubmed:meshHeading | pubmed-meshheading:11173925... | lld:pubmed |
| pubmed-article:11173925 | pubmed:meshHeading | pubmed-meshheading:11173925... | lld:pubmed |
| pubmed-article:11173925 | pubmed:meshHeading | pubmed-meshheading:11173925... | lld:pubmed |
| pubmed-article:11173925 | pubmed:year | 2001 | lld:pubmed |
| pubmed-article:11173925 | pubmed:articleTitle | Effect of the noncompetitive NMDA antagonists MK-801 and ketamine on the spastic Han-Wistar mutant: a rat model of excitotoxicity. | lld:pubmed |
| pubmed-article:11173925 | pubmed:affiliation | Department of Biology, California State University at Northridge, Calif. 91330, USA. | lld:pubmed |
| pubmed-article:11173925 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11173925 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11173925 | lld:pubmed |
